Tuesday 30 June 2020

Biochips Market 2019 - Opportunity, Driving Trends And Deep Study 2023

Global Biochips Market trends held a market value of USD 7,300 million in 2017, according to the MRFR. The market is expected to exhibit a strong 16.6% CAGR over the forecast period from 2018 to 2023, according to the report.
Biochips are intended to function in biological environment, preferably inside living organism. The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications will boost the biochips market size and growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.  
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Competitive Landscape:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.  
The Middle East & Africa has the lowest biochips market share in global market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
Posted by at No comments:

Monday 29 June 2020

Implantable Cardioverter Defibrillator (ICD) Market Top Key Players, Drivers, Revenue, Demand, Analysis And Forecasts To 2025

Market Synopsis
The GlobalImplantable Cardioverter Defibrillator (ICD) Market Size: Increasing prevalence of cardiovascular diseases, growing aging population, and changing lifestyles are projected to boost the market from USD 6,952.2 Million in 2018 to 10,425.96 Million by 2025 at a CAGR of 5.96%.
Top Key Players
Top Implantable Cardioverter Defibrillator (ICD) Market Manufacturers in the Global market are Abbott Laboratories (US), BIOTRONIK (Germany), Boston Scientific Corporation (US), Medtronic (Ireland), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co., Ltd (Japan), Getinge (Sweden), ZOLL Medical Corporation (US), etc.
Market Highlights
According to MRFR analysis, the global implantable cardioverter defibrillator (ICD) market is expected to register a CAGR of 5.96% during the forecast period of 2019 to 2025. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to the American College of Cardiology Foundation, sudden cardiac arrest (SCA) is also one of the leading causes of death worldwide and is responsible for 250,000 to 450,000 deaths per year in the US. Also, coronary artery disease is a major risk factor for sudden cardiac arrest (SCA).
The global implantable cardioverter defibrillator (ICD) market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen their market positions. For instance, in May 2019, the US Food and Drug Administration (FDA) has approved Boston Scientific's Emblem S-ICD that is used in the treatment of cardiovascular diseases. Through this approval, Boston Scientific focuses on strengthening its position in the US ICD market. Medtronic is developing Extravascular (EV) ICD system, an innovative subcutaneous ICD that is designed to terminate arrhythmias, post-shock pacing to protect from sudden cardiac arrest, and temporary back-up bradycardia pacing.
Segmentation
By Type
  • Regular ICD: Holdsthe highest share in the market due to the increasing occurrences and growing incidence rates of autoimmune diseases.
  • Cardiac Resynchronization Therapy Defibrillators (CRT-D): Holds the second-largest share in the market and is expected to grow at a moderate rate during the forecast period. The growth is mainly due to increasing cardiac arrests among patients, R&D by major players, and strategic partnerships
  • Subcutaneous-ICD (S-ICD): Holds the third-largest share in the market and is expected to grow at a steady rate in the market during the forecast period. New product launches, manufacturing facility expansion in emerging countries such as India, China, Brazil, and other emerging countries could drive the market.
  • Others: Covers accessories and small component parts of implantable cardioverter defibrillators. This segment holds the least share in the market.
By Indication
  • Myocardial Ischemia: Myocardial Ischemia is the largest as well as the fastest-growing segment by indication as ICDs are majorly used in the treatment of myocardial ischemia. Moreover, the prevalence rate of sudden cardiac arrests is rising. Myocardial ischemia is further segmented into symptomatic and asymptomatic.
  • Acute Myocardial Infarction: It is the second-largest segment in the market, and this condition is also commonly called a heart attack. Acute myocardial infarction is a life-threatening condition that occurs when blood flow to the heart muscle is abruptly cut off, causing tissue damage. It is the second-largest segment in the market by indication.
  • Electrolyte Imbalance and Drug Toxicity: It is the third-largest and fastest-growing segment in the market.
By End User
  • Hospitals & Clinics: This is the largest and fastest-growing market segment and is projected to grow well beyond the forecast period. Hospitals and clinics are primary care centers for individuals afflicted with type-1 diabetes and are also cost-effective. Moreover, in countries with government-funded healthcare and a high prevalence of type-1 diabetes, hospitals and clinics are the main treatment centers, which drives the growth of the segment.
  • Ambulatory Surgical Centers: A more specialized treatment option, a large number of specialty centers have established across the US and are being opened in developing nations such as India and China. This segment is growing due to the increased number of individuals afflicted with the condition and the higher returns on investment from specialty centers as compared to hospitals and clinics.
  • Others: The ease of availability and delivery of diabetes medication has led to patients opting for home treatment. The segment also covers old age homes as the geriatric population is highly susceptible to type-1 diabetes. The segment is expected to grow as awareness regarding the condition increases along with the ease of treatment.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICD market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The ICDs market in the Americas is likely to hold a major share owing to the increased patient pool. The European ICD market has been sub-divided classified as Western Europe and Eastern Europe. The Western European market has further been classified categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ICD market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific ICD market is projected to be the fastest-growing due to the increasing incidences of acute myocardial infarction and myocardial infraction, growing aging population, and changing lifestyle (smoking and alcohol consumption) in the region. The ICD market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:

Global Diabetic Neuropathy Treatment Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2025

Market Scenario:
The Global Diabetic Neuropathy Treatment Market Share Analysis by MRFR asserts that the industry is expected to cross USD 5.80 Billion by 2025 at a CAGR of 5.1%.
Market Synopsis
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
Market Influencer
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Browse Sample of the Report @ 
Market Drivers
  • Growing global geriatric population.
  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.
  • Increasing research and development of new drugs to treat diabetic neuropathy disorder.
  • Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.
  • Rising awareness of advanced treatments for diabetic neuropathy.
  • Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.
Market Restraints
  • High treatment costs.
  • Availability of alternative therapies such as traditional medicine and physiotherapy.
  • Need for specialized equipment to diagnose and treat diabetic neuropathy.
Segmentation
By Disorder
  • Peripheral Neuropathy: The largest segment of the market, peripheral neuropathy afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.
  • Autonomic Neuropathy: This disorder generally afflicts elderly people. As of 2018, about 23 million people in the US had autonomic neuropathy and over a quarter of those afflicted could not perform daily activities.
  • Proximal Neuropathy: It is a rare type of nerve damage that occurs in hip, buttock, or thigh. It typically affects one side of the body and rarely spreads to the other side of the body. About 50% of patients suffering from diabetes have proximal neuropathy.
  • Focal Neuropathy: This focal neuropathy disorder afflicts roughly 3 out of every ten individuals who have diabetes with over 100 million people affected globally.
By Treatment
  • Drugs: The fastest-growing segment of the market, drugs are most widely used for the treatment of diabetic neuropathy. A rise in the number of FDA approvals for drugs to treat diabetic neuropathy is a key factor for the growth of the segment.
  • Transcutaneous Electrical Nerve Stimulation (TENS): The largest segment, TENS is the preferred treatment for many diabetic neuropathies as they reduce inflammation and suppress immune system activity.
  • Others: The other segment includes physiotherapy and electroacupuncture and various other treatment options for diabetic neuropathy.
By End-User
  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with diabetic neuropathy. Growing awareness and increasing efficiency of diabetic neuropathy treatment are projected to drive the growth of this segment during the forecast period.
  • Retail Pharmacy: A small segment. This center provides immediate pain relief and rudimentary drugs for diabetic neuropathy.
  • Online Pharmacy: Various drugs are used for the treatment of diabetic neuropathy which can be easily available in online pharmacy.
  • Others: This segment includes home care and senior citizen centers.
By Region
  • Americas: The largest regional market. The prevalence of diabetic neuropathy is high in the Americas. The region also has a well-established healthcare industry. Out of the entire population, around 72.2% people in the US were suffering from diabetic neuropathy in 2017.
  • Europe: An increasing geriatric population is leading to a rise in the number of diabetic neuropathy disorder cases.
  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people afflicted with diabetic neuropathy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. Diabetic neuropathy is an increasing problem in Asia. Approximately 4000 patients were diagnosed with diabetic neuropathy in Korea in 2017, whereas in Japan, around 298 people were diagnosed with diabetic neuropathy in 2017.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.Top of FormBottom of Form
Posted by at No comments:

Global Microbiology Testing Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Market Scenario
The Global Microbiology Testing Market is expected to register 10.4% CAGR and is anticipated to reach USD 5409.1 6 Million by 2023. Microbiology testing services help to lower the potential damage risk by microbes and to ensure that the microbiology quality of the products is maintained. The microbial testing technique includes chemical, biological, biochemical, or molecular methods to quantify and identify microbes.
Technological advancements, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are the major drivers propelling market growth. However, erroneous results and high cost of reagents and instruments may constrain the growth of the market.
Key Players
The prominent players in the global microbiology testing market are, Beckman Coulter, Inc. (a subsidiary of Danaher Corp), BioMérieux SA, Thermo Fisher Scientific Inc., Cepheid (a subsidiary of Danaher), and F. Hoffmann-La Roche Ltd.
Some of the key strategies followed by the players operating in the global microbiology testing market were innovation, product development, acquisition, and expansion.
Market Dynamics
Technological advancements are expected to drive the growth of the market. For instance, according to the data published by the National Centre for Health Statistics in 2017, there were around 9,272 cases of tuberculosis infectious disease. Additionally, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are likely to support market growth. On the other hand, erroneous results and high cost of reagents and instruments are anticipated to hamper the market growth.
Segmentation
The global microbiology testing market has been segmented into product type, application, and end user. 
Based on type, the global market has been segmented into instruments, chemicals & reagents, consumables & accessories, and others. The instruments segment accounted for a market value of USD 954.9 million in 2016.
Based on application, the global market has been segmented into gastrointestinal infections, respiratory infections, urinary tract infections, sexually transmitted infections, and others.
Based on end user, the global market has been segmented into hospital associate laboratory, independent laboratory, and academic and research institutes.
Regional Analysis
The global microbiology testing market, based on region, is segmented into North Americas, Europe, Asia-Pacific, and the Middle East & Africa.
North America is estimated to dominate the global microbiology testing market during the forecast period. This can be attributed to the rapid adoption of advanced products and techniques. The European market for microbiology testing is expected to be the second-largest during the forecast period. Increasing innovation and changing laboratory practices is expected to boost the growth of the market in this region.
Asia-Pacific is estimated to be the fastest-growing market due to increasing funding for R&D, developing healthcare infrastructure, growing awareness about microbiology testing, government initiatives to improve public health, and growing investments by major players. Moreover, in the region, South Korea accounted for a market share of 9.2% in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, and limited availability to equipment.
Posted by at No comments:

Covid-19 Outbreak Impact On CBD Market 2020: Latest Trend, Analysis & Forecast 2026

CBD Market Overview: 
The global CBD market has a substantial chance of registering progress with a 125.58% CAGR during the forecast period of 2019 to 2026. Market Research Future (MRFR) studied the market closely and revealed factors that can impact the outcome.  
Among the major factors, growing acceptance in the healthcare industry, rising approval rate by various countries and states, increase in funding for research works, branding, innovation, and others are expected to help the CBD market growth. Also, healthy competition among companies and FDA approvals will help the product gain more market in the coming years.  
However, the approval rate by the FDA is still far away from the normal standard owing to which the market may face some restraints.  
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/8090
COVID-19 Impact Analysis: 
The CBD terpene formulation is known for its use in treating and containment of viral infections. In various countries, researchers are using this as a substance to prevent infections from diverse infections like the COVID-19 novel strain of coronavirus, which is a trouble for densely populated areas. The research is on since the outbreak of the SARS virus in 2002. The substance has proved its mettle as an effective antiviral agent as specific terpenes when it comes in contact with the SARS virus reduce the severity of the disease and eases the possibility of quick recovery (both in-vitro and in-vivo). This entire method takes place as the substance helps in withholding certain protein that replicates the RNA. This further prevents the penetration of healthy cells and replication. 
Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on CBD Market analysis and demographic challenges, showed how it could move forward in the coming years.
CBD Market Segmentation: 
The global CBD market, as mentioned by analysts in the MRFR report, can be segmented on the basis of form, routes of administration, application, source, end user, and product.  
By form, the global market for CBD has been segmented into solid and liquid. The solid form includes capsule/soft gel, hash, CBD crystals, CBD wax, and others. The liquid form includes oil, tincture, cream, e-liquid, and others. The oil segment is the most popular one.  
By route of administration, the report studies the market on the basis of tincture, capsule, inhalation, and aerosol spray.  
By product, the report contains details of food grade and therapeutic grade. The therapeutic grade is getting good traction.  
By application, the report on the CBD market has been segmented into neurogenerative disorder, fibromyalgia, diabetes, protein bars, and energy drinks. In treating diabetes, CBD is getting significant traction. 
By end user, the report digs deep into segments like food & beverage and healthcare. Various research works are spurring the intake of the product in the healthcare segment.  
By source, the global report studying the CBD market reveals segments like organic and inorganic. Lesser side-effects boost the use of the organic segment. 
CBD Market Regional Analysis: 
North America is expected to dominate the CBD market with Canada and the US performing extraordinarily. In Europe, lenient regulations in some countries would help the market in expansion as it will allow researchers to work on new products in a better way.  
CBD Market Competitive Landscape: 
The global market for CBD is benefiting from various companies like Freedom Leaf, Inc, Aphria Inc., Folium Biosciences, CBD Health Solutions, LLC, Green Roads of Florida, LLC, Isodiol International Inc, ENDOCA, Medical Marijuana, Inc., Canopy Growth Corporation, CV Sciences, Inc, and Elixinol Global Limited. This is due to their implementation of diverse strategies, including mergers, joint ventures, acquisitions, and others. These methods often target expansion in the portfolio. The process also gets highlighted by other tactical tools like an investment in research and development, focus on innovations, branding, and launching of latest products to edge out peers. MRFR tracks these companies to find out their latest moves and help in developing a proper strategic move.  
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/report/covid-19-impact-cbd-market 
Posted by at No comments:

Age-Related Macular Degeneration Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market Report insights by MRFR assert, the market expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
Posted by at No comments:

Worldwide Dermal Fillers Market Top 10 Players Universal Analysis, Industry Demand And 2025 Forecast

Dermal Fillers Market Size is expected to register a CAGR of 13.2% and growth to reach USD 6,899.16 Million till 2025.
Dermal fillers are minimally invasive procedures used as anti-aging solutions to reduce facial lines and restore firmness. These are soft tissue fillers injected into the skin to resolve skin-related problems such as scars, wrinkles, and smoothens the skin using various dermal fillers such as hyaluronic acid, polymers and particles, and collagen.
Key factors that drive the dermal fillers market are the rising preference for non-invasive aesthetic procedures, an increasing number of plastic surgeons performing aesthetic procedures, and cost-effective alternatives to cosmetic surgeries. Also, the increase in per capita disposable income boosts the growth of the global dermal fillers market.
However, factors such as side-effects associated with dermal fillers and the black market of dermal fillers and effects of unregistered practitioners hamper the market growth. The increasing number of clinical trial studies and rising demand for minimally invasive procedures act as an opportunity for the market.
Market Dynamics
Growing demand for facial aesthetics globally.
Globally, the demand for facial aesthetic treatments, products, and services is growing at a rapid pace. The growing number of medical aesthetic facilities providing aesthetic services is boosting the growth of the market. Such facilities have made these procedures more accessible and have helped in the rise of the popularity of these practices. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2018, the number of non-surgical cosmetic procedures involving hyaluronic acid was 3,729,833 globally. The cost-effective dermal filler therapy provided by some countries such as China and India are driving the dermal fillers market growth in the region.
The above chart shows the number of procedures involving the use of hyaluronic acid in 2018 and 2017. Females constitute almost ninety percent of the total procedures. This attributes to the increasing inclination of the female population towards the use of dermal fillers. Also, the number of procedures, as seen in the table, has increased from the years 2018 to 2017. The growing awareness about the benefits of the fillers and the need for maintaining youthful structure push the sales of facial injectables. This results in the growing demand for the dermal fillers.
Segmentation
Global Dermal Fillers Market is segmented into Type, Brand, and Application. By type, the market has been segmented into hyaluronic acid, polymers & particles, calcium hydroxylapatite, and collagen. By type hyaluronic acid held the largest market value of USD 1,154.96 million in 2018 and is expected to grow at the highest CAGR during the forecasted year.
Based on brand, the market has been segmented into juvederm, radiesse, and restylane. On the basis of application, the market has been segmented into facial line correction treatment, face-lift, and lip treatments.
Regional Analysis
Global Dermal Fillers Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the global dermal fillers market. The growth of the American market can be attributed to the increasing demand for cosmetic products, growing geriatric population, launching of the new minimally invasive facial procedure, and rising clinical trials to innovate skincare products. According to the annual plastic surgery procedural statistics, there were 17.5 million surgical and minimally invasive cosmetic procedures performed in the US in 2017, with a 2 percent increase in the number of procedures over 2016. The increase in demand for minimally invasive cosmetic procedure drives the market growth in America.
Europe is expected to account for the second-largest market share during the forecast period. The European market is segmented into Germany, the UK, Italy, Spain, France, and the rest of Europe. Europe held a healthy share in the global dermal fillers market and is the second-largest market leader after the Americas, owing to the increasing acceptance of new aesthetic products, growing support by government bodies for the use of minimally invasive dermal procedures, and the increasing number of product approvals & availability of products across the region. For instance, in October 2015, Galderma, a global pharmaceutical company, announced the availability of Emervel, the newest range of hyaluronic acid (HA) dermal fillers in Canada. The launching and availability of new products across the region boost the market.
Asia-Pacific is projected to exhibit the fastest market growth from 2019 to 2025 owing to rapidly booming geriatric population, rising per capita disposable income, escalating demand of facial aesthetics products and increasing awareness about non-invasive cosmetic procedures available in the market. According to the report published by the United Nations Population Fund (UNFPA), it is reported that there will be an increase in the geriatric population in the future and estimated that 1.3 billion people would be above 60 years by 2050 in the Asia-Pacific region. Hence the increasing aging population boosts market growth.
The market in the Middle East and Africa is likely to exhibit the lowest growth owing to limited access to treatment facilities. Moreover, limited developments in technology may slow market growth during the review period. But the growing number of beauty clinics & hospitals in countries such as Saudi Arabia and the launch of new products will help to strengthen the market growth.
Key Players
The Prominent Players in the Global Dermal Fillers Market are Galderma Laboratories, LP (Switzerland), Allergan (Ireland), Merz Pharma (Germany), Dr. Korman Laboratories (Israel), Sinclair Pharma (UK), Teoxane Laboratories (Switzerland), Suneva Medical (US), SciVision Biotech Inc. (Taiwan), Medytox (South Korea), and among others.
Posted by at No comments:
Subscribe to: Posts (Atom)